Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02009501 · ClinicalTrials.gov registry record · NA

V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds

A NA study, sponsored by St. Luke's-Roosevelt Hospital Center.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT02009501 is a NA study that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02009501, a NA study, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

This study would like to determine if using negative pressure wound therapy with an instillation of .125% Dakins is more effective than using negative pressure wound therapy alone on biofilm removal, disruption and elimination in chronically infected lower extremity wounds.

Interventions

  • DEVICE VAC VeraFlo with Dakins Instillation
  • DEVICE VAC Ulta Therapy

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-11
Est. Completion 2015-06
Phase NA

What the Registry Record Tells You About NCT02009501

The ClinicalTrials.gov registry entry for NCT02009501 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which VAC VeraFlo with Dakins Instillation is the first listed.

NCT02009501 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02009501 about?

NCT02009501 is a clinical study titled "V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds". This study would like to determine if using negative pressure wound therapy with an instillation of .125% Dakins is more effective than using negative pressure wound therapy alone on biofilm removal, disruption and elimination in chronically infected lower extremity wounds.

What is the current status of trial NCT02009501?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-11. Estimated completion is 2015-06.

What interventions are being tested in trial NCT02009501?

The interventions under investigation include: VAC VeraFlo with Dakins Instillation (DEVICE), VAC Ulta Therapy (DEVICE).

Who is sponsoring clinical trial NCT02009501?

This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.